article thumbnail

The Five Major Tech Trends of 2016

Xconomy

As we draw closer to the end of 2016, it is important that we take a moment to look back and reflect on all of the ways technology has inspired us, and transformed the way we live and do work. The Continued Growth of Cloud.

article thumbnail

Episona Gets $4M For Male Infertility Testing

socalTECH

According to Episona, the funding came from the Pasadena Angeles, as well as other high-net worth individuals from Pasadena and San Francisco. Episona has been offering up its test since October of 2016. Episona develops an epigenetic test which examines DNA for risk factors related to male factor fertility and poor embryo quality.

Pasadena 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

United Dwelling is one startup building something to solve California’s housing crisis

TechCrunch LA

After wrestling with recalcitrant homeowners, husbanding their parcels of land to keep their property values high, the state’s leadership passed a law that increased the availability of new rental units and put more money into homeowners’ pockets in 2016. The Culver City, Calif.-based

article thumbnail

Is Venture Capital A Path To Riches?

InfoChachkie

Thus, it’s entirely appropriate that founders net substantially more than the VC partners associated with their company. A few of the 2016 presidential candidates have indicated their intent to change the rate at which venture returns are taxed. For instance, in the above scenarios, a founder who owns 15% would gross between $22.7

article thumbnail

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. I widened my net this year. The results were so encouraging, we’re doing it again.

article thumbnail

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales. Talk about sacrifice.

article thumbnail

Privacy Advocate Richard Holober on the Tech Backlash of 2017 

Xconomy

Speculation is rampant about a possible sea change in consumer attitudes toward the tech industry and its products—a shift that might affect sales, the regulatory environment, and other factors important to companies. We’ve just passed a year full of news about the role of technology companies in U.S.